nach oben

Medical Oncology

Erschienen in:

01.03.2013 | Original Paper

Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer

verfasst von: Wenwei Hao, Yongping Zhu, Huifang Zhou

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate serum levels of interleukin-6 (IL-6) and interleukin-8 (IL-8) as prognostic variables in patients with laryngeal squamous cell cancer. A total of 92 patients with primary diagnosis of laryngeal squamous cell cancer (LSCC), treated between 2003 and 2005, were included in this evaluation. Preoperative serum levels of IL-6 and IL-8 were measured by enzyme-linked immunosorbent assay methods. Results were compared according to clinical and pathological date criteria. Serum IL-6 and IL-8 levels were significantly higher in patients with LSCC compared to healthy controls (P < 0.0001). Serum IL-6 level was associated with lymph node metastasis (P < 0.001), T classification (P < 0.001) and clinical stage (P = 0.001). Multivariate analysis indicated that serum IL-6 was an independent predictor of LSCC-specific progression-free survival (P = 0.049) and overall survival (P = 0.040). Higher serum IL-6 level (IL-6 > 9.7 pg/ml) was associated with a shortened overall survival and progression-free survival (P < 0.05). Our data indicate that serum IL-6 is associated with the development and progression of LSCC. Serum IL-6 may serve as an independent prognostic marker for LSCC patients.

Ramroth H, Schoeps A, Rudolph E, Dyckhoff G, Plinkert P, Lippert B, et al. Factors predicting survival after diagnosis of laryngeal cancer. Oral Oncol. 2011;47(12):1154–8.PubMedCrossRef

Li XY, Guo X, Feng S, Li XT, Wei HQ, Yang HA et al. Relationship between a family history of malignancy and the incidence of laryngeal carcinoma in the Liaoning province of China. Clinical otolaryngology: official journal of ENT-UK; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery. 2009;34(2):127–31.

Ji W, Guan C, Pan Z. Analysis of curative effects on laryngeal carcinoma patients in the northeast region of China. Acta Otolaryngol. 2008;128(5):574–7.PubMedCrossRef

Almadori G, Bussu F, Paludettii G. Predictive factors of neck metastases in laryngeal squamous cell carcinoma. Towards an integrated clinico-molecular classification. Acta otorhinolaryngologica Italica: organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale. 2006;26(6):326–34.

Gourin CG, Conger BT, Sheils WC, Bilodeau PA, Coleman TA, Porubsky ES. The effect of treatment on survival in patients with advanced laryngeal carcinoma. Laryngoscope. 2009;119(7):1312–7.PubMedCrossRef

Johansen LV, Grau C, Overgaard J. Laryngeal carcinoma–multivariate analysis of prognostic factors in 1252 consecutive patients treated with primary radiotherapy. Acta Oncol. 2003;42(7):771–8.PubMedCrossRef

Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev. 2006;32(7):504–15.PubMedCrossRef

Nguyen-Tan PF, Le QT, Quivey JM, Singer M, Terris DJ, Goffinet DR, et al. Treatment results and prognostic factors of advanced T3–4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys. 2001;50(5):1172–80.PubMedCrossRef

Seiler P, Plenz G, Deng MC. The interleukin-6 cytokine system in embryonic development, embryo-maternal interactions and cardiogenesis. Eur Cytokine Netw. 2001;12(1):15–21.PubMed

10.

Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol. 2000;60(8):1185–95.PubMedCrossRef

11.

Horn F, Henze C, Heidrich K. Interleukin-6 signal transduction and lymphocyte function. Immunobiology. 2000;202(2):151–67.PubMedCrossRef

12.

Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250(2):607–10.PubMedCrossRef

13.

Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15(14):3651–8.PubMed

14.

Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 1997;57(1):141–6.PubMed

15.

Suarez-Cuervo C, Harris KW, Kallman L, Vaananen HK, Selander KS. Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat. 2003;80(1):71–8.PubMedCrossRef

16.

Barille S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw. 2000;11(4):546–51.PubMed

17.

Starska K, Lukomski M, Jozefowicz-Korczynska M, Glowacka E. Production of proinflammatory cytokines IL-6 and IL-8 by peripheral blood lymphocytes T under influence in vitro of squamous cell carcinoma of the larynx. Pol Otolaryngol. 2007;61(4):626–32.CrossRef

18.

Derin D, Soydinc HO, Guney N, Tas F, Camlica H, Duranyildiz D, et al. Serum IL-8 and IL-12 levels in breast cancer. Med Oncol. 2007;24(2):163–8.PubMedCrossRef

19.

Konno H, Ohta M, Baba M, Suzuki S, Nakamura S. The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci. 2003;94(8):735–40.PubMedCrossRef

20.

Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol. 2008;19(10):1734–41.PubMedCrossRef

21.

Tjiong MY, van der Vange N, ten Kate FJ, Tjong AHSP, ter Schegget J, Burger MP, et al. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol. 1999;73(2):285–91.PubMedCrossRef

22.

Zhou DH, Trauzold A, Roder C, Pan G, Zheng C, Kalthoff H. The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell. Hepatobiliary Pancreat Dis Int. 2008;7(2):201–9.PubMed

23.

Vinante F, Rigo A, Vincenzi C, Ricetti MM, Marrocchella R, Chilosi M, et al. IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. Leukemia. 1993;7(10):1552–6.PubMed

24.

Li A, Varney ML, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res. 2001;7(10):3298–304.PubMed

25.

Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen P, et al. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol. 2012;18(10):1123–9.PubMedCrossRef

26.

Liu TR, Xu LH, Yang AK, Zhong Q, Song M, Li MZ, et al. Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients. PLoS ONE. 2012;7(7):e40704.PubMedCrossRef

27.

Szczepanik AM, Scislo L, Scully T, Walewska E, Siedlar M, Kolodziejczyk P, et al. IL-6 serum levels predict postoperative morbidity in gastric cancer patients. Gastric Cancer. 2011;14(3):266–73.PubMedCrossRef

28.

Alcover J, Filella X, Luque P, Molina R, Izquierdo L, Auge JM, et al. Prognostic value of IL-6 in localized prostatic cancer. Anticancer Res. 2010;30(10):4369–72.PubMed

29.

Urquidi V, Chang M, Dai Y, Kim J, Wolfson ED, Goodison S, et al. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol. 2012;12:12.PubMedCrossRef

30.

Rubie C, Frick VO, Pfeil S, Wagner M, Kollmar O, Kopp B, et al. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol. 2007;13(37):4996–5002.PubMed

31.

Hou T, Tieu BC, Ray S, Recinos A III, Cui R, Tilton RG, et al. Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev. 2008;4(3):179–92.PubMedCrossRef

32.

Jee SH, Chu CY, Chiu HC, Huang YL, Tsai WL, Liao YH, et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Investig Dermatol. 2004;123(6):1169–75.PubMedCrossRef

Titel: Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer
verfasst von: Wenwei Hao
Yongping Zhu
Huifang Zhou
Publikationsdatum: 01.03.2013
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-012-0333-6

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer

Abstract

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis

Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study

Positive expression of Lin28 is correlated with poor survival in gastric carcinoma

Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma

MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma

CD44 and CD27 expression pattern in B cell precursor acute lymphoblastic leukemia and its clinical significance

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie